New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
NCT00035854 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 13
Last updated 2009-08-14
Summary
This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
Conditions
Interventions
- DRUG
-
Zyvox® / Linezolid
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-02-28
- Completion
- 2004-05-31
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin
NCT01561469 ·Status: COMPLETED
-
Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.
NCT04126031 ·Status: TERMINATED ·Phase: PHASE2
-
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
NCT00037050 ·Status: COMPLETED ·Phase: PHASE3
-
Use of a Loading Dose of Vancomycin in Pediatric Dosing
NCT01290237 ·Status: TERMINATED ·Phase: NA
-
Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus
NCT00572559 ·Status: COMPLETED ·Phase: PHASE4
-
The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents
NCT00811980 ·Status: COMPLETED
-
Linezolid in Healthy Volunteers
NCT03841721 ·Status: UNKNOWN ·Phase: PHASE1
-
Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection
NCT00304811 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children
NCT02694458 ·Status: COMPLETED ·Phase: NA
-
Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.
NCT06423898 ·Status: RECRUITING ·Phase: PHASE4
-
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
NCT02208063 ·Status: TERMINATED ·Phase: PHASE3
-
Population Pharmacokinetics of Linezolid
NCT01200654 ·Status: COMPLETED ·Phase: PHASE4
-
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
NCT02814916 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus
NCT02701608 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
NCT00695903 ·Status: TERMINATED ·Phase: PHASE2
-
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
NCT04775953 ·Status: COMPLETED ·Phase: PHASE2
-
Model-informed Precision Dosing for Linezolid
NCT06444802 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Resistant Bacteria in Children in France
NCT06036628 ·Status: COMPLETED
-
Cost Effectiveness Of Linezolid In Central America
NCT01040585 ·Status: WITHDRAWN
-
Intrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis
NCT02143154 ·Status: COMPLETED
-
Linezolid-resistant Staphylococcus Epidermidis in ICU and Risk Factors Analysis
NCT03140410 ·Status: UNKNOWN
-
Optimization of Bacterial Vaginosis Treatment in Women of Reproductive Age
NCT06458543 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)
NCT02750761 ·Status: COMPLETED ·Phase: PHASE1
-
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
NCT01792804 ·Status: COMPLETED ·Phase: PHASE3
-
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
NCT00519025 ·Status: COMPLETED